Total Utang marang Modal BeOne Medicines (BGNE)

BeiGene - logo grafis emiten BGNE

The daily price chart for BeiGene, Ltd. (BGNE) on the GURU.Markets platform demonstrates the financial resilience of a business whose revenue is decoupled from economic cycles and GDP fluctuations. The current total debt-to-equity ratio stands at 0.41. BeiGene, Ltd. (BGNE) is implementing sustainable laboratory standards and bioethics, while the expansion of Brukinsa effectively covers the costs of global R&D.

beigene.com (BGNE): Rasio Utang marang Ekuitas saka 04.07.2022 nganti 31.10.2026

Rincian metrik lan analitis perusahaan BeiGene Ltd (BGNE)

- rega saham lan konsensus proyeksi valuasi:
Rega saham BeiGene|BGNE - Target konsensus
- rincian kapitalisasi pasar:
Kapitalisasi pasar BeiGene|BGNE - Nilai Perusahaan
- indikator kapitalisasi buku:
Aset Bersih saben Siji Saham BeiGene|BGNE - Kapitalisasi Akuntansi|Rasio Kapitalisasi Pasar marang Nilai Buku beigene.com|BGNE - Gunggung Aset Perusahaan
- rincian utang lan likuiditas:
Total Utang marang Modal BeiGene, Ltd.|BGNE - Kewajiban jangka dawa marang modal|Utang jangka cendhak marang ekuitas BeiGene, Ltd.|BGNE - Kewajiban utang agregat|Utang marang nilai buku BeiGene|BGNE - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan BeiGene|Indikator likuiditas cepet beigene.com
- data bathi resik lan rasio valuasi:
BGNE - Bathi resik
Pambiji fundamental perusahaan:BeiGene
Produk dadi BeiGene, Ltd.

The ambitions of BeiGene, Ltd. (BGNE) management to achieve global leadership in oncology therapy require colossal investments in clinical trials and expansion. By analyzing the company's debt-to-equity ratio, an investor assesses the proportion of borrowed funds within the financing structure relative to net assets. The dynamics of this metric allow for the determination of the balance between utilizing leverage for growth and the risks to the business's financial stability.

Analisis pesaing BeiGene, Ltd.

ONC (BeiGene) - Total Utang marang Modal|Rasio Total Utang marang Ekuitas Halozyme Therapeutics, Inc. (HALO)|Total Utang marang Modal RVMD|Total Utang marang Modal Ascentage Pharma Corp (AAPG)|Utang marang Ekuitas CG Oncology, Inc. CGON|URGN: Rasio Utang marang Ekuitas|Bicara Therapeutics - Total Utang marang Modal|Personalis Inc (PSNL) - Rasio Total Utang marang Ekuitas|ERAS: Total Utang marang Modal|Utang marang Modal Delcath Corp (DCTH)|Utang marang Ekuitas Y-mAbs Therapeutics|AURA: Rasio Kabeh Utang marang Dana Pribadi|Rasio Total Utang marang Ekuitas CADL (Candel Therapeutics)|ARAY (Accuray Inc) - Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal SLS (SELLAS Life Sciences Group)|ACTU - Rasio Total Utang marang Ekuitas|CTOR: Rasio Total Utang marang Ekuitas|HURA - Total Utang marang Modal|Protara Therapeutics, Inc. (TARA) - Utang marang Ekuitas|Fate Therapeutics Inc - Rasio Kabeh Utang marang Dana Pribadi|WHWK (Aadi Bioscience, Inc.) - Total Utang marang Modal|Utang marang Modal TScan TCRX|Total Utang marang Modal CSBR|Utang marang Ekuitas XBIT (xbiotech.com)|Total Utang marang Modal CVM (CEL-SCI)|OS Therapies Inc. (OSTX) - Utang marang Modal|Radiopharm Theranostics Limited - Total Utang marang Modal|Koefisien Total Utang marang Modal Artiva Biotherapeutics, Inc. ARTV|ANL: Total Utang marang Modal|Rasio Utang marang Modal verupharma.com VERU|TPST (Tempest Therapeutics, Inc.) - Total Utang marang Modal|Utang marang Modal Xilio XLO|Utang marang Ekuitas Renovaro Inc. (RENB)|muraloncology.com - Rasio Utang marang Ekuitas|Total Utang marang Modal KAPA (Kairos Pharma)|OnKure Therapeutics, Inc. (OKUR) - Utang marang Modal|GDTC: Rasio Total Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi CRIS (Curis, Inc.)|apollomicsinc.com (APLM) - Utang marang Ekuitas|THAR (Tharimmune Corporation) - Utang marang Ekuitas|Rasio Total Utang marang Ekuitas ADVB|GNPX (genprex.com) - Utang Agregat marang Modal|Total Utang marang Modal CLDI|Sunshine Biopharma Inc. - Rasio Utang marang Ekuitas|Xenetic Biosciences, Inc. - Rasio Total Utang marang Ekuitas|Koefisien Total Utang marang Modal Salarius Pharma (SLRX)|Purple Biotech - Total Utang marang Modal|AONC: Utang marang Ekuitas|CKPT: Total Utang marang Modal|Rasio Utang marang Modal elevationoncology.com ELEV|Utang marang Ekuitas iCAD Inc.|Rasio Utang marang Ekuitas IKNA (Ikena)|Total Utang marang Modal NTBL|VIRX - Utang marang Modal|Total Utang marang Modal MOR (MorphoSys)|NAYA - Rasio Total Utang marang Ekuitas|Ascentage Pharma Group Ltd - Total Utang marang Modal